The active compound in the best-selling drug Ozempic markedly lowers the risk of complications from chronic kidney disease, according to a multiyear study published Friday — a finding that could ...

Novo Nordisk's GLP-1 agonist Ozempic has become the first drug in the class to be approved by the FDA to reduce the risk of worsening kidney disease in people with type 2 diabetes. The approval ...

Wegovy and Ozempic are both semaglutide weight loss medications, but they’re prescribed differently based on who qualifies.

Ozempic is already approved to treat T2D, for cardiovascular risk reduction ... worsening kidney disease and cardiovascular death in people with T2D and CKD. …as Rybelsus cuts MACE in type ...

The Food and Drug Administration says it has seized several hundred units of fake versions of Ozempic. The drug maker Novo Nordisk told the FDA that the counterfeit 1-milligram injections were ...

A new study suggests that semaglutide, the active ingredient in Ozempic, may help decrease liver fat, inflammation, and ...

The announcement follows new research that suggested drugs like Wegovy, Mounjaro and Ozempic slashed the risk of contracting the disease. Scientists from Israel said the drugs, also known as GLP ...

Nearly twice as many people taking semaglutide stopped their fatty liver disease without further scarring of the organ, ...

Two new studies published in JAMA Neurology reveal that GLP-1 receptor agonists, like Ozempic and Trulicity ... GLP-1 drugs cut 45% lower risk of dementia. Similar findings were published in ...